• 

  Plain language results in UK clinical trials: Navigating new regulatory requirements and practical challenges

  2026-04-08T14:23:00+01:00

• 

  The regulatory valuation of patient experience data in rare diseases: A review of FDA and EMA labelling outcomes and methodological determinants

  2026-04-07T13:21:00+01:00

• 

  Regulatory Rapporteur March 2026 – Contents

  2026-03-06T09:18:00+00:00

• 

  The innovation era: Where biology meets technology

  2026-03-05T17:58:00+00:00

• 

  The EU’s Health Technology Assessment Regulation: Implementation one year on

  2026-03-05T16:15:00+00:00

• 

  Beyond product approval: Bridging the gap between regulatory success and patient access for biosimilars

  2026-03-05T14:52:00+00:00

• 

  WMA declarations: Helsinki in the spotlight and Taipei in the background

  2026-03-04T17:31:00+00:00

• 

  Navigating Advanced Therapy Medicinal Product regulatory changes: European Medicines Agency and UK guidance updates

  2026-03-04T17:04:00+00:00

• 

  Cell therapy, gene therapy and tissue-engineered product manufacturing: Technical challenges, enablers and regulatory evolution

  2026-03-04T15:08:00+00:00

• 

  Navigating regulatory pathways for live biotherapeutics in the US and EU: Challenges and opportunities

  2026-03-04T12:15:00+00:00

• 

  New ICH M15 Guideline sets harmonised framework for MIDD

  2026-02-18T11:04:00+00:00

• 

  MHRA points to clinical trial growth and faster assessment routes

  2026-01-28T09:44:00+00:00

More pharmaceutical content